Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

259.93
-1.6600-0.63%
Pre-market: 261.001.07+0.41%05:35 EDT
Volume:3.89M
Turnover:1.01B
Market Cap:459.40B
PE:73.43
High:262.32
Open:260.51
Low:259.00
Close:261.59
52wk High:269.39
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.03
T/O Rate:0.22%
Dividend:6.83
Dividend Rate:2.63%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-77.40
PE(LYR):110.14

Loading ...

Abbvie - Partnership to Accelerate Small Molecule Drug Discovery in Immunology, Neuroscience, Oncology

THOMSON REUTERS
·
Sep 21

Adarx Pharmaceuticals: IPO Price Expected Between $15 and $17 Per Share

Reuters
·
Sep 21

ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO

Dow Jones
·
Sep 21

Drug Developer ADARx Seeks $1.74 Billion Valuation in US IPO

Reuters
·
Sep 21

AbbVie presents new Vraylar data at Psych Congress 2026

TIPRANKS
·
Sep 18

AbbVie Says Real-World Studies Show Vraylar Improves Symptoms in MDD, Bipolar I Depression

Reuters
·
Sep 18

AbbVie Targets Dry Eye Market Upside With New ABBV-444 Trial Update

TIPRANKS
·
Sep 18

US Regulators Urge More Research on Testosterone Therapy for Women as Experts Debate Benefits, Risks

Reuters
·
Sep 18

Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A

Reuters
·
Sep 17

AbbVie’s Allergan Aesthetics presents clinical data on skin quality improvement

TIPRANKS
·
Sep 17

Abbvie Exec Says Will Present Late-Stage Data for Blood Cancer Drug Etentamig at International Myeloma Society Meeting Later in September - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Existing Portfolio Provides 'Clear Line of Sight' to Very Strong Growth Well into Next Decade - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Apogee Fits 'Very Nicely' with Its Business Development Approach - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Plans to Start Enrolling Apogee's Zumilokibart This Year, Targets Launch in Early 2030 - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Tavapadon U.S. Launch Expected to Have 'Slower Burn' Due to Timing of Medicare Reimbursement - Conf Call

THOMSON REUTERS
·
Sep 15

Testosterone Scripts for Women Rise, Along with Denials and Delays

Reuters
·
Sep 15

RBC Capital Sticks to Their Buy Rating for AbbVie (ABBV)

TIPRANKS
·
Sep 15

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

AbbVie Announces Q4 2026 Dividend of R$ 0.37 Per Unit, Payable Nov. 23

Reuters
·
Sep 12

AbbVie’s ECLIPSE Migraine Trial Completes, Setting Up a New Catalyst for ABBV

TIPRANKS
·
Sep 12